Document is current
Any future updates will be listed below
-
Authors
Hutchinson, Jonathan P.
Rowland, Paul
Taylor, Mark R. D.
Christodoulou, Erica M.
Haslam, Carl
Hobbs, Clare I.
Holmes, Duncan S.
Homes, Paul
Liddle, John
Mole, Damian J. https://orcid.org/0000-0001-6884-7302
Uings, Iain
Walker, Ann L.
Webster, Scott P.
Mowat, Christopher G.
Chung, Chun-wa
- License Information
-
More Information
Article History
Received: 7 January 2017
Accepted: 28 April 2017
First Online: 12 June 2017
Competing interests
: GlaxoSmithKline holds patents on the molecules described in the paper. J.P.H., P.R., E.M.C., C.H., C.I.H., D.S.H., P.H., J.L., I.U., A.L.W. and C.C. are employees of GlaxoSmithKline but do not receive any direct remuneration based on the success of this specific project. M.R.D.T., D.J.M., S.P.W. and C.G.M. work for the University of Edinburgh which is engaged in a Discovery Partnership with Academia collaboration with GlaxoSmithKline by which the University of Edinburgh receives milestone according to the phase of development of the KMO inhibitors described and would receive royalty payments on any resulting commercial sales. These payments are governed by the University of Edinburgh revenue sharing policy.
